ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
10.53
-0.10 (-0.94%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.31 - 10.78
52 week 10.31 - 20.25
Open 10.62
Vol / Avg. 628,649.00/922,076.00
Mkt cap 903.62M
P/E     -
Div/yield     -
EPS -0.78
Shares 85.81M
Beta 1.90
Inst. own 91%
Aug 13, 2014
Immunogen Inc at Canaccord Genuity Growth Conference - 3:30PM EDT - Add to calendar
Aug 1, 2014
Q4 2014 Immunogen Inc Earnings Call - 8:00AM EDT - Add to calendar
Aug 1, 2014
Q4 2014 ImmunoGen, Inc. Earnings Release - 6:30AM EDT - Add to calendar
Jun 4, 2014
ImmunoGen, Inc. at Jefferies Global Healthcare Conference
May 14, 2014
ImmunoGen, Inc. at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -544.76% -204.90%
Operating margin -544.65% -205.46%
EBITD margin - -192.40%
Return on average assets -77.19% -36.97%
Return on average equity -131.79% -70.78%
Employees 245 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company�s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company's TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
David B. Johnston Chief Financial Officer, Executive Vice President, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Charles Q. Morris Executive Vice President, Chief Development Officer
Age: 48
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Eric Guempel Vice President - Product Strategy and Program Management
Bio & Compensation  - Reuters
James J. O'Leary M.D. Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Theresa G. Wingrove Ph.D. Vice President - Regulatory Affairs
Age: 55
Bio & Compensation  - Reuters